Table 1.
Baseline characteristics of study cohorts
| Parameter | Cirrh-to-No HCC | Cirrh-to-HCC | CHC | Healthy |
|---|---|---|---|---|
| Subjects, n | 38 | 11 | 11 | 12 |
| HLA-A2-positive patients, n | 17 | 5 | 0 | 5 |
| Male sex, n (%) | 21 (55) | 8 (73) | 6 (55) | 4 (33) |
| Age, years | ||||
| Median | 59 | 60 | 55 | 49 |
| Range | 35–79 | 47–80 | 30–74 | 40–81 |
| HCV genotype, n (%) | ||||
| 1 | 28 (74) | 9 (82) | 6 (55) | n.a. |
| 3 | 10 (26) | 2 (18) | 5 (45) | n.a. |
| IFN-free therapy, n | ||||
| Sof | 15 | 5 | 3 | n.a. |
| Sof-Dac | 11 | 0 | 2 | n.a. |
| Sof-Sim | 7 | 1 | 0 | n.a. |
| Sof-Velp | 0 | 0 | 1 | n.a. |
| Sof-Led | 3 | 4 | 3 | n.a. |
| Omb-Par-Das | 2 | 1 | 2 | n.a. |
| Treatment outcome, n | ||||
| SVR | 33 | 11 | 11 | n.a. |
| Relapse | 5 | 0 | 0 | n.a. |
| Meld score | ||||
| Median | 9 | 9 | 7 | n.a. |
| Range | 7–18 | 7–20 | 6–10 | n.a. |
| Above median/total, n (%) | 11/38 (29) | 5/11 (45) | 1/11 (9) | n.a. |
| Albumin, g/L | ||||
| Median | 35.5 | 31 | 40 | n.a. |
| Range | 24–43 | 17–42 | 37–47 | n.a. |
| Above median/total, n (%) | 19/38 (50) | 5/11 (45) | 5/11 (45) | n.a. |
| Platelets, tsd/ìL | ||||
| Median | 91.5 | 102 | 211 | n.a. |
| Range | 33–346 | 48–130 | 113–280 | n.a. |
| Above median/total, n (%) | 19/38 (50) | 5/11 (45) | 5/11 (45) | n.a. |
| Bilirubin, ìmol/l | ||||
| Median | 17.5 | 16 | 10 | n.a. |
| Range | 6–78 | 9–70 | 4–21 | n.a. |
| Above median/total, n (%) | 19/38 (50) | 5/11 (45) | 4/11 (36) | n.a. |
| Fibroscan, kPa | ||||
| Median | 32 | 30.2 | 5.9 | n.a. |
| Range | 14.4–75 | 17–75 | 4.1–14.3 | n.a. |
| Above median/total, n (%) | 17/35 (49) | 5/10 (50) | 4/11 (36) | n.a. |
| Unknown | 3/38 (8) | 1/11 (9) | n.a. | n.a. |
| Alanine aminotransferase, U/L | ||||
| Median | 90.5 | 69 | 74 | n.a. |
| Range | 28–289 | 21–267 | 17–394 | n.a. |
| Above median/total, n (%) | 19/38 (50) | 4/11 (36) | 5/11 (45) | n.a. |
| Aspartate aminotransferase, U/L | ||||
| Median | 86.5 | 106 | 56 | n.a. |
| Range | 39–281 | 37–182 | 20–146 | n.a. |
| Above median/total, n (%) | 19/38 (50) | 5/11 (45) | 5/11 (45) | n.a. |
n.a., not applicable; CHC, chronic hepatitis C; Sof, sofosbuvir; Sim, simeprevir; Dac, daclatasvir; Led, ledipasvir; Velp, velpatasvir; Omb, ombitasvir; Par, paritaprevir; Das, dasabuvir.